Gorgojo-Martinez JJ, et al. - An exploration was pursued of the effectiveness of exenatide once-weekly (ExQW) in patients with type 2 diabetes (T2D). This study also incorporated an identification of the predictors of glycaemic and weight response to this drug at 6 months. A substantial decrease was attained in A1C, weight, blood pressure and lipids at 6 months via ExQW therapy, in a real-world setting. Higher baseline A1C was discovered to be the sole independent predictor of glycaemic response to ExQW. Furthermore, higher BMI and previous DDP4i treatment were unveiled as predictive factors of significant weight response.